Search tips
Search criteria 


Logo of transbThe Royal Society PublishingPhilosophical Transactions BAboutBrowse By SubjectAlertsFree Trial
Philos Trans R Soc Lond B Biol Sci. 2011 January 12; 366(1561): 94–98.
PMCID: PMC3001306

Ageing and protein aggregation-mediated disorders: from invertebrates to mammals


Late onset is a common hallmark character of numerous disorders including human neurodegenerative maladies such as Huntington's, Parkinson's and Alzheimer's diseases. Why these diseases manifest in aged individuals and why distinct disorders share strikingly similar emergence patterns were until recently unsolved enigmas. During the past decade, invertebrate-based studies indicated that the insulin/IGF signalling pathway (IIS) mechanistically links neurodegenerative-associated toxic protein aggregation and ageing; yet, until recently it was unclear whether this link is conserved from invertebrates to mammals. Recent studies performed in Alzheimer's mouse models indicated that ageing alteration by IIS reduction slows the progression of Alzheimer's-like disease, protects the brain and mitigates the behavioural, pathological and biochemical impairments associated with the disease. Here, we review these novel studies and discuss the potential of ageing alteration as a therapeutic approach for the treatment of late onset neurodegeneration.

Keywords: ageing, proteotoxicity, neurodegeneration, insulin/IGF-1 signalling

1. Neurodegenerative disorders

Late age onset is the most striking common feature of human neurodegenerative disorders, such as Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) and non-infectious prion diseases. In the cases of AD and PD, the minority of cases manifest as mutation-linked, familial cases during the patient's fifth decade, while most cases appear sporadically not earlier than the seventh decade of life. HD is a familial, monogenic disease that similarly to other familial neurodegenerative disorders onsets during the patient's fifth decade of life [1]. This common occurrence pattern defines ageing as the major risk factor for the development of these maladies [2] and raises the principal question of whether the ageing process plays an active mechanistic role in enabling neurodegeneration to onset late in life. During the past decade, studies based on invertebrate models revealed mechanistic links between ageing and the onset of toxic protein aggregation [35].

Aggregation, accumulation and deposition of aberrantly folded proteins are mechanistic unifying features of neurodegenerative disorders [6]. In AD, a dual digestion of the amyloid precursor protein (APP) by the proteases β and γ secretases, releases a subset of highly aggregative peptides, collectively termed amyloid β (Aβ) including Aβ1–40 and the highly aggregative Aβ1–42. Aβ aggregation results in neural loss, cognitive impairments and eventually to death [7]. Similarly, the aggregation of α-synuclein underlies the development of PD [8]; the aggregation of mutated huntingtin (Htt), bearing an abnormally long polyglutamine stretch, causes HD [1]; and aggregation of the prion protein (PrP) leads to prion disorders [9]. Clinical observations [10] as well as experimental discoveries [11,12] indicated that not high-molecular weight (high-MW) Aβ fibrils but small oligomers are the major toxic species that are best correlated with neurotoxicity and with AD. Similarly, small PrP aggregates are the most toxic PrP species [13]. By the development of an automated microscope and the expression of fluorescently tagged aggregative mutated Htt, the Finkbeiner laboratory has found that the formation of inclusion bodies containing aggregated Htt promotes neuronal survival [14].

2. The insulin/igf-1 signalling pathway regulates ageing in worms and mammals

At least three independent mechanisms regulate ageing and lifespan; dietary restriction (DR) [15], the mitochondrial electron transport chain [1618] and the insulin/IGF signalling pathway (IIS) [19]. The IIS is the best studied and exhibits the most prominent effects on the lifespans of worms and flies. In the nematode Caenorhabditis elegans, the sole insulin/IGF receptor, DAF-2, initiates a signalling cascade that mediates the phosphorylation of its downstream FOXO transcription factor DAF-16. Phosphorylated DAF-16 is prevented from entering the nucleus and from regulating its target genes [20]. Thus, daf-2 knockdown hyperactivates DAF-16 creating youthful, long-lived worms [21]. Several mouse models indicated that this ageing regulating pathway is conserved in mice. First, a mouse strain harbouring only one copy of the IGF-1 receptor (IGF-1R), the closest daf-2 orthologue in mammals, exhibited long life and stress resistance [22].The longevity phenotype was more prominent in females but was also observed to a lesser extent in males. Similarly, the abolishment of the insulin receptor in the mouse adipose tissues (FIRKO mice) lead to longevity [23]. Although it is under debate whether the insulin receptor substrate (IRS) 2 is involved in the regulation of lifespan in the mouse [24,25], it was recently shown that mice lacking IRS 1 are long-lived [26].

Recently, several reports indicated correlation between lower IIS activity and extreme human longevity. Mutations in the IGF-1 receptor leading to lower activity of the IGF-1 signalling pathway were found to be more abundant among Jewish Ashkenazi centenarians than in control groups [27]. Similarly, mutations within FOXO3a (the closest daf-16 mammalian orthologue) were found to be correlated with human longevity of two distinct centenarian groups, Japanese-Hawaiian [28] and German [29]. IRS2 variants were also reported to correlate with longevity in an Italian population [30]. Together these studies strongly suggest that the roles of the IIS as lifespan determinant are conserved in humans.

3. Insulin/igf signalling pathway reduction protects worms for toxic protein aggregation

Slowing ageing by IIS reduction in worms expressing aggregative, disease-linked proteins, indicated that in these models, the IIS directly exposes the aged organism to the toxicity associated with protein aggregation (reviewed in Balch et al. [31]). Morley et al. [5] showed that IIS reduction by age-1 RNAi or mutations mitigates the toxic effects of fluorescently tagged polyQ aggregates in the body wall muscles of worms as measured by impaired motility. The protective effect towards polyQ aggregation was found to be dependent on the heat shock factor 1 (HSF-1), a key player in the longevity effect of reduced IIS [4,32]. We reported previously that IIS reduction protects worms from the toxic effects of Aβ aggregation in DAF-16- and HSF-1-dependent manners. These transcription factors were found to mediate opposing activities: HSF-1 promotes disaggregation while DAF-16 facilitates protective active aggregation [3]. This protective effect was apparent in the worm model even when the alteration of IIS was applied late in life [33]. Together these studies point to IIS reduction as a promising novel approach for the development of counter-neurodegenerative therapy. However, rodent-based studies revealed that IGF-1 infusion protects from Aβ-mediated toxicity [34] and that blocking the IGF-1R exacerbates AD-like symptoms in model mice and results in neurodegeneration [35]. These studies, which apparently contradict the findings obtained from the worm systems, raised the prospect that IIS induction might protect from proteotoxicity [36]. Thus, it was critically required to evaluate whether IIS reduction delays the onset of the behavioural, pathological and biochemical impairments apparent in mammalian neurodegeneration models or whether IIS reduction accelerates neurodegeneration in mice.

4. The counter-proteotoxic effect of insulin/igf signalling pathway reduction is conserved from worms to mammals

Three independent research groups have recently addressed these questions by crossing AD model mouse strains with animals that exhibit reduced IIS. Killick et al. [37] used transgenic mice that harbour mutated human APP gene carrying the Swedish mutation (K670N, M671L) under the PrP promoter (Tg2576 mice [38]). These animals were created on the C57Bl/6 background and typically develop observable Aβ plaques in the brain at seven to eight month of age. Tg2576 mice were crossed with C57Bl/6 mice that lack the insulin receptor substrate 2 (Irs2−/−) to obtain AD animals that lack the IRS2 gene (Tg2576/Irs2−/−). Comparison of 12 month old Tg2576/Irs2−/− and their age-matched Tg2576 counterparts revealed that IIS reduction by Irs2 deletion resulted in significant reduction in Aβ plaque burden in the brain. Furthermore, the plaques seen in brains of Tg2576/Irs2−/−animals were smaller than those of Tg2576 controls. Interestingly, no differences in soluble and metabolized Aβ fractions were observed among the different mouse genotypes but Tg2576/Irs2−/− had significantly less aggregative Aβ, suggesting that the deletion of Irs2 enhances Aβ clearance capabilities. Surprisingly, elevated phosphorylation rates of the microtubule associated protein TAU, a hallmark of AD [39], were detected in brains of Tg2576/Irs2−/− animals. Apparently, the elevated TAU phosphorylation resulted predominantly from the abolishment of IRS-2 and not the aggregation of Aβ. Next the researchers employed the fear conditioning test to measure whether Irs2 knockout mice were rescued from learning and memory deficits associated with Tg2576 animals [40] and found that Tg2576/Irs2−/− mice exhibit significantly improved performance when compared with the Tg2576 controls. This study indicated that IIS reduction by the abolishment of IRS-2 confers protection from neurotoxicity associated with the aggregation of Aβ in the brain. Since IRS-2 null mice are short-lived [25,26], this study indicates that longevity and the counter-proteotoxic functions of IIS reduction can be uncoupled.

In a separate study, Freude et al. [41] adopted a similar approach and crossed Tg2576 mice (on the C57Bl/6 background) with either: Irs2−/− mice (these animals had the same genetic design as those studied by Killick et al. [37], yet the Irs2−/− mice used in the two studies were created by different laboratories), mice which lack the IGF-1 receptor in neurons (nIGF-1R−/−), or mice lacking the insulin receptor in their neurons (nIR−/−). The rationale behind these crosses was based on two observations: (i) the levels of IRS-2, IGF-1 receptor and of the insulin receptor have been reported to be abnormally low in brains of AD patients [42] and (ii) reduced levels of these molecules have been linked to longevity [22,23,43]. The abolishment of IRS-2 rescued Tg2576/Irs2−/− females, but not males, from premature mortality typical of Tg2576 animals (it has been proposed that Tg2576/Irs2−/− males exhibited short lifespan owing to hyperglycemia) [41]. Although APP levels were comparable in 12 week old Tg2576 and aged matched Tg2576/Irs2−/− counterparts, Western blot and ELISA analyses revealed significantly less Aβ1–40 in the latter mouse group. By contrast, no differences in Aβ1–40 and Aβ1–42 levels could be detected in older animals (48 weeks of age). To explore the mechanism underlying the reduced Aβ levels observed in young Tg2576/Irs2−/− mice, the researchers measured the amounts of BACE-1 (the β secretase) and its activity levels in 12 week old Tg2576 and Tg2576/Irs2−/− mice and found no significant differences. Yet the amounts of the βC terminal fragment (βCTF) were lower in Tg2576/Irs2−/− when compared with Tg2576 animals suggesting an enhanced Aβ clearance capability in the absence of IRS-2 [41]. This result is correlated with the finding that the insulin degrading enzyme (IDE), a protease known to digest Aβ [44] is more abundant in the membrane fractions of Tg2576/Irs2−/−compared with their Tg2576 counterparts [37].

To specifically investigate the roles of IGF-1 signalling in the brain, the researchers used the Tg2576/nIGF-1R−/−mouse strains. These animals exhibited reduced IGF-1R levels in the hippocampus but not in other brain structures or in peripheral organs. Lifespan experiments indicated that both Tg2576/nIGF-1R−/− males and females were protected from the premature death typical of Tg2576 mice. Unlike old Tg2576/Irs2−/− (60 weeks of age) mice, Tg2576/nIGF-1R−/− animals had lower amounts of Aβ1–40 and Aβ1–42 when compared with their age matched Tg2576 counterparts, showing that the abolishment of IGF-1R in the hippocampus has a more prominent counter-proteotoxic effect than organismal IRS-2 elimination. AD mice harbouring only one Igf-1R copy in neurons (Tg2576/nIGF-1R + / − ) and those lacking the insulin receptor in their neurons (Tg2576/nIR + / − ) showed no effect on survival when compared with Tg2576 animals [41].

Both studies described above clearly indicated that IIS reduction by either the abolition of IRS-2 or by neuron-specific elimination of the IGF-1 receptor protected mice from toxicity associated with the aggregation of the human Aβ peptide. Yet the key questions of what is the protective mechanism and whether there are effects on a variety of AD-associated brain pathologies remained unanswered. To address whether the counter-proteotoxic effects of IIS reduction which we discovered in the worm system [3] are conserved in mice and in order to explore the underlying protective mechanism, we crossed AD-model mice with a well-established long-lived mouse strain that harbours only one copy of the gene encoding the Igf-1 receptor to create long-lived AD animals. We selected an AD model strain that expresses two mutated AD-linked genes, humanized APPswe (mouse APP that was mutated to harbour the human Aβ sequence) and human presenilin1 (PS1) lacking exon 9 (the regulatory exon of PS1). Both transgenes were driven by the mouse PrP promoter (APPswe/P1ΔE9 mice) [45]. These mice develop relatively slow age-dependent neurodegenerative symptoms similarly to AD patients, including behavioural impairments [46], neuro-inflammation and Aβ plaque formation [45]. To achieve reduced IGF-1 signalling, we selected the long-lived, stress resistant Igf1R+/− mouse strain [22]. First, we equalized the genetic background of our mice by backcrossing both mouse strains with 129Xi females; next we crossed the strains to obtain APPswe/P1ΔE9 with reduced IGF-1 signalling (APPswe/P1ΔE9/Igf1R+/−). The behavioural performances of 12–13 month old APPswe/P1ΔE9/Igf1R+/− were significantly better than those of their age-matched APPswe/P1ΔE9 counterparts in a battery of behavioural assays, indicating that IGF-1 signalling reduction largely protected the mice from AD-associated memory and orientation impairments. Consistently, the rates of neuro-inflammation, neuronal and synaptic losses were all mitigated by IGF-1 signalling reduction in brains of aged mice (12–13 month of age) [47]. The total Aβ amounts as well as the levels of APP processing enzymes were indistinguishable in APPswe/P1ΔE9 and APPswe/P1ΔE9/Igf1R+/− mice.

We found that Aβ plaques were smaller in size and of higher density in AD-model mice with reduced IGF-1 signalling when compared with their littermates which had natural IGF-1 signalling. To further establish this observation we employed post-embedding electron microscopy analysis and developed an automated algorithm designed to identify Aβ plaques by locating gold particles conjugated to Aβ antibodies, defining an area of interest around them and measuring their densities. This algorithm based assay, with in vitro and biochemical assays, confirmed that reduction of IGF-1 signalling led to the compaction of Aβ plaques in brains of APPswe/P1ΔE9/Igf1R+/− mice. This compaction probably protects the brain by sequestering highly toxic Aβ oligomers [47]. This protective mechanism is common to Aβ worms whose IIS was reduced [3] and to the APPswe/P1ΔE9/Igf1R+/− mice [47].

5. The therapeutic potential of insulin/igf signalling pathway reduction for neurodegeneration

The three recent studies reviewed here adopted similar approaches, found similar findings (summarized in table 1) and reached consistent conclusions that IIS reduction protects AD-model mice from Aβ aggregation-associated proteotoxicity. These recent developments in the field and the discoveries that (i) Aβ quantities in brains of protected animals with reduced IIS were similar to those found in brains of their unprotected counterparts and (ii) IIS reduction led to the formation of Aβ plaques of higher densities, strongly support the theme that Aβ oligomers are the major toxic species that are correlated with AD. Accordingly, in mammals, hyperaggregation probably serves as a protective mechanism that is negatively regulated by the ageing process. Thus, ageing exposes the organism to the toxicity of oligomers and enables neurodegenerative disorders to manifest late in life.

Table 1.
Comparison of AD-like associated parameters in the different mouse models.

Together, the protection towards AD-like disorders in mice and the findings that the regulation of ageing by the IIS is conserved in humans point to the promising therapeutic potential of IIS reduction for the treatment of a variety of neurodegenerative disorders. IGF signalling inhibitors might be able to serve as novel, powerful drugs aimed at preventing the onset of neurodegenerative maladies and slowing their progression once emerged.


One contribution of 15 to a Discussion Meeting Issue ‘The new science of ageing’.


1. Bates G. 2003. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361, 1642–1644 (doi:10.1016/S0140-6736(03)13304-1)10.1016/S0140-6736(03)13304-1 [PubMed] [Cross Ref]
2. Amaducci L., Tesco G. 1994. Aging as a major risk for degenerative diseases of the central nervous system. Curr. Opin. Neurol. 7, 283–286 (doi:10.1097/00019052-199408000-00001)10.1097/00019052-199408000-00001 [PubMed] [Cross Ref]
3. Cohen E., Bieschke J., Perciavalle R. M., Kelly J. W., Dillin A. 2006. Opposing activities protect against age-onset proteotoxicity. Science 313, 1604–1610 (doi:10.1126/science.1124646)10.1126/science.1124646 [PubMed] [Cross Ref]
4. Hsu A. L., Murphy C. T., Kenyon C. 2003. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300, 1142–1145 [PubMed]
5. Morley J. F., Brignull H. R., Weyers J. J., Morimoto R. I. 2002. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 99, 10 417–10 422 (doi:10.1073/pnas.152161099)10.1073/pnas.152161099 [PubMed] [Cross Ref]
6. Kopito R. R., Ron D. 2000. Conformational disease. Nat. Cell Biol. 2, E207–E209 (doi:10.1038/35041139)10.1038/35041139 [PubMed] [Cross Ref]
7. Selkoe D. J. 2004. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140, 627–638 [PubMed]
8. Lee V. M., Trojanowski J. Q. 2006. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33–38 (doi:10.1016/j.neuron.2006.09.026)10.1016/j.neuron.2006.09.026 [PubMed] [Cross Ref]
9. Aguzzi A., Polymenidou M. 2004. Mammalian prion biology: one century of evolving concepts. Cell 116, 313–327 (doi:10.1016/S0092-8674(03)01031-6)10.1016/S0092-8674(03)01031-6 [PubMed] [Cross Ref]
10. Haass C., Selkoe D. J. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. 8, 101–112 [PubMed]
11. Shankar G. M., et al. 2008. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837–842 (doi:10.1038/nm1782)10.1038/nm1782 [PMC free article] [PubMed] [Cross Ref]
12. Townsend M., Shankar G. M., Mehta T., Walsh D. M., Selkoe D. J. 2006. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477–492 [PubMed]
13. Silveira J. R., Raymond G. J., Hughson A. G., Race R. E., Sim V. L., Hayes S. F., Caughey B. 2005. The most infectious prion protein particles. Nature 437, 257–261 (doi:10.1038/nature03989)10.1038/nature03989 [PMC free article] [PubMed] [Cross Ref]
14. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R., Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (doi:10.1038/nature02998)10.1038/nature02998 [PubMed] [Cross Ref]
15. Mair W., Dillin A. 2008. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem. 77, 727–754 (doi:10.1146/annurev.biochem.77.061206.171059)10.1146/annurev.biochem.77.061206.171059 [PubMed] [Cross Ref]
16. Dillin A., Hsu A. L., Arantes-Oliveira N., Lehrer-Graiwer J., Hsin H., Fraser A., G., Kamath R. S.,, Ahringer J., Kenyon C. 2002. Rates of behavior and aging specified by mitochondrial function during development. Science 298, 2398–2401 [PubMed]
17. Feng J., Bussiere F., Hekimi S. 2001. Mitochondrial electron transport is a key determinant of life span in Caenorhabditis elegans. Dev. Cell 1, 633–644 (doi:10.1016/S1534-5807(01)00071-5)10.1016/S1534-5807(01)00071-5 [PubMed] [Cross Ref]
18. Lee S. S., Lee R. Y., Fraser A. G., Kamath R. S., Ahringer J., Ruvkun G. 2003. A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. Nat. Genet. 33, 40–48 (doi:10.1038/ng1056)10.1038/ng1056 [PubMed] [Cross Ref]
19. Kenyon C., Chang J., Gensch E., Rudner A., Tabtiang R. 1993. A C. elegans mutant that lives twice as long as wild type. Nature 366, 461–464 (doi:10.1038/366461a0)10.1038/366461a0 [PubMed] [Cross Ref]
20. Lee R. Y., Hench J., Ruvkun G. 2001. Regulation of C. elegans DAF-16 and its human ortholog FKHRL1 by the daf-2 insulin-like signaling pathway. Curr. Biol. 11, 1950–1957 (doi:10.1016/S0960-9822(01)00595-4)10.1016/S0960-9822(01)00595-4 [PubMed] [Cross Ref]
21. Kenyon C. 2001. A conserved regulatory system for aging. Cell 105, 165–168 (doi:10.1016/S0092-8674(01)00306-3)10.1016/S0092-8674(01)00306-3 [PubMed] [Cross Ref]
22. Holzenberger M., Dupont J., Ducos B., Leneuve P., Geloen A., Even P. C., Cervera P., Le Bouc Y. 2003. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182–187 (doi:10.1038/nature01298)10.1038/nature01298 [PubMed] [Cross Ref]
23. Bluher M., Kahn B. B., Kahn C. R. 2003. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572–574 (doi:10.1126/science.1078223)10.1126/science.1078223 [PubMed] [Cross Ref]
24. Selman C., Lingard S., Gems D., Partridge L., Withers D. J. 2008. Comment on ‘Brain IRS2 signaling coordinates life span and nutrient homeostasis’. Science 320, 1012 (author reply 1012) (doi:10.1126/science.1152366)10.1126/science.1152366 [PubMed] [Cross Ref]
25. Taguchi A., Wartschow L. M., White M. F. 2007. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317, 369–372 (doi:10.1126/science.1142179).10.1126/science.1142179 [PubMed] [Cross Ref]
26. Selman C., et al. 2008. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 22, 807–818 (doi:10.1096/fj.07-9261com)10.1096/fj.07-9261com [PubMed] [Cross Ref]
27. Suh Y., Atzmon G., Cho M. O., Hwang D., Liu B., Leahy D. J., Barzilai N., Cohen P. 2008. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc. Natl Acad. Sci. USA 105, 3438–3442 (doi:10.1073/pnas.0705467105)10.1073/pnas.0705467105 [PubMed] [Cross Ref]
28. Willcox B. J., et al. 2008. FOXO3A genotype is strongly associated with human longevity. Proc. Natl Acad. Sci. USA 105, 13 987–13 992 (doi:10.1073/pnas.0801030105)10.1073/pnas.0801030105 [PubMed] [Cross Ref]
29. Flachsbart F., Caliebe A., Kleindorp R., Blanche H., von Eller-Eberstein H., Nikolaus S., Schreiber S., Nebel A. 2009. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc. Natl Acad. Sci. USA 106, 2700–2705 (doi:10.1073/pnas.0809594106)10.1073/pnas.0809594106 [PubMed] [Cross Ref]
30. Barbieri M., Rizzo M. R., Papa M., Boccardi V., Esposito A., White M. F., Paolisso G. 2010. The IRS2 Gly1057Asp variant is associated with human longevity. J. Gerontol. A 65, 282–286 [PubMed]
31. Balch W. E., Morimoto R. I., Dillin A., Kelly J. W. 2008. Adapting proteostasis for disease intervention. Science 319, 916–919 (doi:10.1126/science.1141448).10.1126/science.1141448 [PubMed] [Cross Ref]
32. Morley J. F., Morimoto R. I. 2004. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell 15, 657–664 (doi:10.1091/mbc.E03-07-0532)10.1091/mbc.E03-07-0532 [PMC free article] [PubMed] [Cross Ref]
33. Cohen E., Du D., Joyce D., Kapernick E. A., Volovik Y., Kelly J. W., Dillin A. 2010. Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection. Aging Cell 9, 126–134 (doi:10.1111/j.1474-9726.2009.00541.x).10.1111/j.1474-9726.2009.00541.x [PMC free article] [PubMed] [Cross Ref]
34. Carro E., Trejo J. L., Gomez-Isla T., LeRoith D., Torres-Aleman I. 2002. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8, 1390–1397 (doi:10.1038/nm793)10.1038/nm793 [PubMed] [Cross Ref]
35. Carro E., Trejo J. L., Spuch C., Bohl D., Heard J. M., Torres-Aleman I. 2006. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol. Aging 27, 1618–1631 (doi:10.1016/j.neurobiolaging.2005.09.039)10.1016/j.neurobiolaging.2005.09.039 [PubMed] [Cross Ref]
36. Gasparini L., Xu H. 2003. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 26, 404–406 (doi:10.1016/S0166-2236(03)00163-2)10.1016/S0166-2236(03)00163-2 [PubMed] [Cross Ref]
37. Killick R., et al. 2009. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem. Biophys. Res. Commun. 386, 257–262 (doi:10.1016/j.bbrc.2009.06.032)10.1016/j.bbrc.2009.06.032 [PMC free article] [PubMed] [Cross Ref]
38. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99–102 (doi:10.1126/science.274.5284.99).10.1126/science.274.5284.99 [PubMed] [Cross Ref]
39. Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M., Blinder L. I. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913–4917 (doi:10.1073/pnas.83.13.4913)10.1073/pnas.83.13.4913 [PubMed] [Cross Ref]
40. Jacobsen J. S., et al. 2006. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5161–5166 (doi:10.1073/pnas.0600948103)10.1073/pnas.0600948103 [PubMed] [Cross Ref]
41. Freude S., et al. 2009. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 23, 3315–3324 (doi:10.1096/fj.09-132043)10.1096/fj.09-132043 [PubMed] [Cross Ref]
42. Moloney A. M., Griffin R. J., Timmons S., O'Connor R., Ravid R., O'Neill C. 2010. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224–243 (doi:10.1016/j.neurobiolaging.2008.04.002)10.1016/j.neurobiolaging.2008.04.002 [PubMed] [Cross Ref]
43. Taguchi A. W. M. 2008. Insulin-like signaling, nutrient homeostasis, and life span. Annu. Rev. Physiol. 70, 191–212 (doi:10.1146/annurev.physiol.70.113006.100533)10.1146/annurev.physiol.70.113006.100533 [PubMed] [Cross Ref]
44. Leissring M. A., Farris W., Chang A. Y., Walsh D. M., Wu X., Sun X., Frosch M. P., Selkoe D. J. 2003. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087–1093 (doi:10.1016/S0896-6273(03)00787-6)10.1016/S0896-6273(03)00787-6 [PubMed] [Cross Ref]
45. Jankowsky J. L., Slunt H. H., Ratovitski T., Jenkins N. A., Copeland N. G., Brochelt D. R. 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157–165 (doi:10.1016/S1389-0344(01)00067-3)10.1016/S1389-0344(01)00067-3 [PubMed] [Cross Ref]
46. Reiserer R. S., Harrison F. E., Syverud D. C., McDonald M. P. 2007. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 6, 54–65 (doi:10.1111/j.1601-183X.2006.00221.x)10.1111/j.1601-183X.2006.00221.x [PubMed] [Cross Ref]
47. Cohen E., et al. 2009. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157–1169 (doi:10.1016/j.cell.2009.11.014)10.1016/j.cell.2009.11.014 [PMC free article] [PubMed] [Cross Ref]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society